Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 4/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | CACNA1G | O43497 | 7/20 | 0.38 |
| ▸ | CACNA1I | Q9P0X4 | 7/20 | 0.38 |
| ▸ | CACNA1H | O95180 | 6/20 | 0.38 |
| ▸ | LDHB | P07195 | 1/20 | 0.37 |
| ▸ | STIM1 | Q13586 | 1/20 | 0.35 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.35 |
| ▸ | ORAI3 | Q9BRQ5 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1167847 | 0.92 | SMN1; SMN2 (0.46) | SMN1; SMN2NPSR1HPGDCYP1A2CYP3A4 | |
| SCHEMBL1166631 | 0.91 | NPSR1 (0.43) | SMN1; SMN2NPSR1HPGDCYP1A2CYP3A4 | |
| SCHEMBL1167011 | 0.89 | CACNA1G (0.44) | SMN1; SMN2LMNACACNA1GCACNA1ICACNA1H | |
| SCHEMBL1167409 | 0.85 | CACNA1G (0.48) | SMN1; SMN2NPSR1HPGDCYP1A2CYP3A4 | |
| SCHEMBL1167293 | 0.84 | SMN1; SMN2 (0.44) | SMN1; SMN2NPSR1HPGDCYP1A2CYP3A4 | |
| SCHEMBL1166978 | 0.83 | SMN1; SMN2 (0.42) | SMN1; SMN2HPGDCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL1166472 | 0.82 | LDHB (0.42) | SMN1; SMN2CYP1A2CYP2C9CYP2C19CACNA1G | |
| SCHEMBL1167829 | 0.82 | CACNA1G (0.48) | SMN1; SMN2NPSR1HPGDCYP1A2CYP3A4 | |
| SCHEMBL1166901 | 0.79 | NPSR1 (0.41) | SMN1; SMN2NPSR1HPGDCYP1A2CYP3A4 | |
| SCHEMBL1166909 | 0.79 | NPSR1 (0.40) | SMN1; SMN2NPSR1HPGDCYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2242743-B1 | AMINOPYRAZOLE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2013-08-21 | — | — | EP | claimed |
| US-8288419-B2 | Aminopyrazole derivatives | ACTELION PHARMACEUTICALS, LTD (CH) | 2012-10-16 | — | — | US | claimed |
| US-20110034516-A1 | AMINOPYRAZOLE DERIVATIVES | ACTELION (CH) | 2011-02-10 | — | — | US | claimed |
| EP-2242743-B1 | AMINOPYRAZOLE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2013-08-21 | — | — | EP | disclosed |
| US-8288419-B2 | Aminopyrazole derivatives | ACTELION PHARMACEUTICALS, LTD (CH) | 2012-10-16 | — | — | US | disclosed |
| US-20110034516-A1 | AMINOPYRAZOLE DERIVATIVES | ACTELION (CH) | 2011-02-10 | — | — | US | disclosed |
| EP-2242743-A1 | AMINOPYRAZOLE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2010-10-27 | — | — | EP | disclosed |
| WO-2009077954-A1 | AMINOPYRAZOLE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2009-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034516-A1 | AMINOPYRAZOLE DERIVATIVES | CYP3A43, CYP1A2, CYP3A5 | SMN1; SMN2 4612/4885NPSR1 578/4885HPGD 735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.